To evaluate effect of immunotherapy .
Not Applicable
Completed
- Conditions
- Health Condition 1: - Health Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
- Registration Number
- CTRI/2024/02/062655
- Lead Sponsor
- HCG NCHRI Cancer Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Recurrent and Metastatic head and neck cancer patients who received Immunotherapy from September 2022 to September 2023
Exclusion Criteria
study does not have exclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to measure overall survival rate, duration of response and progression free survivalTimepoint: After starting immunotherapy, every three weeks
- Secondary Outcome Measures
Name Time Method OT APPLICABLETimepoint: NOT APPLICABLE